TD Cowen analyst Tyler Van Buren raised the firm’s price target on Gilead (GILD) to $125 from $115 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results while increasing their total liver and Trodelvy estimates while decreasing total cell therapy and Veklury.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead terminated Phase 1 study of ‘1219, says RBC Capital
- Galapagos price target raised to $28 from $27 at RBC Capital
- Galapagos intends to wind down cell therapy business
- Gilead Sciences Completes Promising Study on Metastatic Colorectal Cancer Treatment
- Gilead, AstraZeneca, and Roche Data Signal New Growth in Cancer Drug Market